Bedrock Therapeutics, Inc.
Publicly observedChapel Hill, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Chapel Hill | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Bedrock Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | SB2ZXJBQ4SX3 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant19 Sept 2025Publicly observed
NIH SBIR/STTR award: Intramuscular Administration of AAV Vectors Encoding soluble PD-L1 for Rheumatoid Arthritis Treatment
USD 304,502.00 · National Institute of Arthritis and Musculoskeletal and Skin Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Aug 2025Publicly observed
NIH SBIR/STTR award: Vector mediated anti-vascular and anti-inflammatory therapy for AMD
USD 310,952.00 · National Eye Institute · Source: NIH RePORTER (opens in a new tab)
- Grant30 Sept 2020Publicly observed
NIH SBIR/STTR award: Prevention of corneal transplant rejection using AAV-BDRK-401 therapy
USD 793,930.00 · National Eye Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.